United Therapeutics CorpAdd to My Watchlist

UTHR:USNASDAQ GSIndustry: Medical-Biomedical/Gene
  • 93.63
    Last
  • 2.30  -2.40%
    Today's Change
  • 95.93
    Previous Close
  • Today
     
    59.05
    116.65
    52 Week Low - High
5:20 pm ET 4/23/2014
Intraday data is at least 15 minutes delayed; All prices are in the local currency; Time is ET.
Stock Price Details
Shares Outstanding50 million
Market Cap$5 billion
Return on Equity ttm14.55%
Last DividendUTHR:US does not pay a dividend
Earnings
EPS: Year Actual ttm3.280
EPS: Year Est. 12/14 ttm11.950
 
EPS: Quarterly Actual 12/13 2.88
EPS: Quarterly Est. 3/14 2.44
 
Price/Earnings ttm28.55
Relative Price/Earnings1.651
Earnings Growth Rate-40.24
Company Description
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.
Revenue$1 billion
Net Income$175 million
Total Assets$2 billion
Employees543
Web Sitewww.unither.com

Latest Headlines

No news available.

    Watchlist

    Unless indicated otherwise: intraday data is at least 15 minutes delayed; mutual fund NAVs are updated at the close of every market day; all prices are in the local currency; Time is ET.

    Sign In Now

     

    Not Registered?

    Get complete access to The Washington Post online - it's FREE!